1449597-34-5
|
|
- CAS号:
- 1449597-34-5
- 英文名:
- SMN-C3
- 英文别名:
- SMN-C3;4H-Pyrido[1,2-a]pyrimidin-4-one, 2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-ethyl-4-piperidinyl)-9-methyl-
- 中文名:
- 1449597-34-5
- 中文别名:
- 化合物SMN-C3;化合物 T12935
- CBNumber:
- CB33069865
- 分子式:
- C24H28N6O
- 分子量:
- 416.52
- MOL File:
- 1449597-34-5.mol
|
|
|
1449597-34-5化学性质
-
密度:
-
1.31±0.1 g/cm3(Predicted)
-
|
-
储存条件:
-
Store at -20°C
-
|
-
溶解度:
-
DMSO : 5 mg/mL (12.00 mM);Water : < 0.1 mg/mL (insoluble)
-
|
-
酸度系数(pKa):
-
9.27±0.10(Predicted)
-
|
1449597-34-5性质、用途与生产工艺
SMN-C3 是一种可口服的 SMN2 剪接调节剂,可用于脊椎肌肉萎缩 (SMA) 的研究。
At P16, vehicle treated D7 mice are much smaller than heterozygous littermate controls and appear moribund. In contrast, D7 mice treated with the high dose of SMN-C3 show a phenotype similar to that of heterozygous controls. SMN-C3 treatment induces a dose-dependent bodyweight gain in the D7 mice, with some animals showing a body weight that is ~80% that of heterozygous controls. SMN-C3 normalizes the motor behavior of D7 mice, illustrated by the ability of the mice to right themselves as quickly as heterozygous controls and by their level of locomotor activity. Most importantly, whereas vehicle-treated mice die within 3 weeks after birth with a median survival of 18 days, SMN-C3 treatment increases survival in a dose-dependent manner to a median survival time of 28 days in the low-dose (0.3 mg/kg per day) group. In the two higher-dose groups (1 and 3 mg/kg per day), ~90% of animals survive beyond P65 when the study is completed.
1449597-34-5
上下游产品信息
上游原料
下游产品
更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
---|
2024/04/30 | HY-112633 | SMN-C3 | | 1 mg | 2200元 |
2024/04/30 | HY-112633 | 1449597-34-5 SMN-C3 | 1449597-34-5 | 5mg | 5500元 |
1449597-34-5, 1449597-34-5 相关搜索:
- APIS
- 化合物SMN-C3
- 化合物 T12935
- 1449597-34-5
- 4H-Pyrido[1,2-a]pyrimidin-4-one, 2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-ethyl-4-piperidinyl)-9-methyl-
- SMN-C3